StreetInsider.com News Articles

Form EFFECT Nuwellis, Inc.

Thu, 27 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260827/26984176.html

Form EFFECT Nuwellis, Inc.

Thu, 27 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260827/26984176.html

Form 424B3 Nuwellis, Inc.

Wed, 26 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260826/26982814.html

Form 424B3 Nuwellis, Inc.

Wed, 26 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260826/26982814.html

Form 8-K Nuwellis, Inc. For: Aug 25

Wed, 26 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260826/26976825.html

Form 8-K Nuwellis, Inc. For: Aug 25

Wed, 26 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260826/26976825.html

Nuwellis strikes co-promotion deal with Atrility Medical for AtriAmp

Tue, 25 Aug 2026 08:32:34 -0400

Nuwellis, Inc. (NASDAQ: NUWE) and Atrility Medical, Inc. have entered into a co-promotion and distribution agreement for Atrility's AtriAmp device, the companies announced.

Under the agreement, the two companies will begin a six-month co-promotion program covering three Nuwellis sales territories across approximately nine Western and five Southeastern states. Nuwellis will receive commissions on sales to existing and new customers within those territories. Atrility will continue to serve its existing customers in the covered areas while Nuwellis pursues new customer relationships.

If the pilot program is completed successfully, Nuwellis is expected to transition to Atrility's exclusive U.S. distributor for much of the country,

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

MINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, and Atrility Medical, Inc, a cardiac medical technology company, today announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp® device.

“AtriAmp is an excellent strategic fit with Nuwellis' growing pediatric and critical care portfolio, serving many of the same hospitals, physicians and care teams that our commercial organization supports today,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “This staged agreement is

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

Form S-3 Nuwellis, Inc.

Tue, 18 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260818/26944996.html

Form S-3 Nuwellis, Inc.

Tue, 18 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260818/26944996.html

Form SCHEDULE 13G/A Nuwellis, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26926349.html

Form SCHEDULE 13G/A Nuwellis, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26926349.html

Form 8-K Nuwellis, Inc. For: Aug 13

Thu, 13 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260813/26922089.html

Form 8-K Nuwellis, Inc. For: Aug 13

Thu, 13 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260813/26922089.html

Form 10-Q Nuwellis, Inc. For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920929.html

Form 10-Q Nuwellis, Inc. For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920929.html

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Thu, 13 Aug 2026 08:00:00 -0400

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027

Conference call begins at 9:00 a.m. Eastern time today

MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026.